Endoscopic Sleeve Gastroplasty Saves Cost Compared With Semaglutide for Class II Obesity
A Brigham and Women’s Hospital study suggests endoscopic sleeve gastroplasty (ESG) is cost-saving compared with semaglutide for class II obesity due to greater effectiveness and lower costs of ESG and increased dropout rates over time with semaglutide.
Read More...